# A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

> **NCT03474679** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 19 (actual)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03474679
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2021-11-29
- **Final completion:** 2021-11-29
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474679, "A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03474679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*